{"id":2118,"date":"2015-01-07T15:26:13","date_gmt":"2015-01-07T20:26:13","guid":{"rendered":"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-2014-activity-report-a-year-of-partnerships\/"},"modified":"2024-09-25T16:29:41","modified_gmt":"2024-09-25T20:29:41","slug":"cqdm-2014-activity-report-a-year-of-partnerships","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-2014-activity-report-a-year-of-partnerships\/","title":{"rendered":"CQDM 2014 Activity Report: A year of partnerships"},"content":{"rendered":"\n

Montreal, January 7th<\/sup>, 2015<\/strong> \u2013 CQDM is pleased to announce the publication of its 2014 Activity Report<\/a>. Proud of the progress made in the last year, 2014 was the year of partnerships. In addition to welcoming Sanofi Canada into its consortium, CQDM extended its collaborations throughout Canada and globally.<\/p>\n\n\n\n

CQDM now has an outstanding portfolio<\/a> of 35 projects<\/strong> carried out by a network of 460 researchers<\/strong> in 51 organizations throughout Canada. These projects all aim to develop breakthrough technologies to improve biopharmaceutical R&D.<\/p>\n\n\n\n

Twelve (12) projects have now been completed with a success rate of more than 90%<\/strong> with 85% of the technologies developed now in use<\/strong> by CQDM pharma members in their internal R&D process. Many of these projects also led to meaningful direct partnerships being created between the researchers funded by CQDM and our pharma members. We should also mention the involvement of more than 100 mentors<\/strong> from CQDM\u2019s pharmaceutical members in the accomplishment of the funded projects.<\/p>\n\n\n\n

CQDM would like to thank its sponsors: Merck, Pfizer Canada, AstraZeneca, Boehringer Ingelheim, Eli Lilly Canada, GlaxoSmithKline, Novartis Pharma Canada and Sanofi Canada; the Quebec Ministry of Economy, Innovation and Exports (MEIE) and the Government of Canada (Business-Led Networks of Centres of Excellence Program, BL-NCE); as well as its cofunding partners (CIHR, Brain Canada, the Ontario Brain Institute, the Ontario Centres of Excellence, MaRS Innovation, Alsace BioValley, Lyonbiopole and the Massachusetts Life Sciences Center). Not only do they bring financial support to the research projects, but their involvement has been immeasurable.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

About CQDM
<\/em><\/strong>CQDM is a pharma-based consortium active in pre-competitive research whose mission is to fund the development of innovative tools and technologies to accelerate drug discovery. Unique in the world, CQDM\u2019s business model is based on a collaborative approach where all stakeholders share the costs of biopharmaceutical research and benefit from its results. CQDM also provides a common meeting ground where academia, governments, and the pharmaceutical and biotechnology industries converge to address numerous complex medical challenges. CQDM receives financial support from <\/em>Merck, Pfizer Canada, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly Canada, Novartis Pharma Canada<\/em>, Sanofi Canada, as well as from Quebec\u2019s Ministry of Economy, Innovation and Exports (MEIE) and under the Federal government\u2019s Business-Led Networks of Centres of Excellence Program (BL-NCE).<\/em>For more information, visit us at <\/em>www.cqdm.org<\/em><\/a>.
<\/em>
Source:
<\/strong>Eug\u00e9nie Bergeron-C\u00f4t\u00e9
Project Coordinator, CQDM
Tel.: (514) 766-6661, ext. 2196
ebergeron@cqdm.org<\/a>
www.cqdm.org<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Montreal, January 7th, 2015 \u2013 CQDM is pleased to announce the publication of its 2014 Activity Report. Proud of the progress made in the last year, 2014 was the year of partnerships. In addition to welcoming Sanofi Canada into its consortium, CQDM extended its collaborations throughout Canada and globally. CQDM now has an outstanding portfolio of 35 projects carried out by…<\/p>\n","protected":false},"author":2,"featured_media":951,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2118","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=2118"}],"version-history":[{"count":2,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2118\/revisions"}],"predecessor-version":[{"id":4444,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2118\/revisions\/4444"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/951"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=2118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=2118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=2118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}